Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation

Mohammad Hedayati, Michael C. Haffner, Jonathan B. Coulter, Raju R. Raval, Yonggang Zhang, Haoming Zhou, Omar Mian, Emma J. Knight, Nina Razavi, Susan Dalrymple, John Tod Isaacs, Aileen Santos, Russell Hales, William G Nelson, S Yegnasubramanian, Theodore DeWeese

Research output: Contribution to journalArticle

Abstract

Purpose: The current standard of care for patients with locally advanced prostate cancer is a combination of androgen deprivation and radiation therapy. Radiation is typically given with androgen suppression when testosterone levels are at their nadir. Recent reports have shown that androgen stimulation of androgen-deprived prostate cancer cells leads to formation of double-strand breaks (DSB). Here, we exploit this finding and investigate the extent and timing of androgen-induced DSBs and their effect on tumor growth following androgen stimulation in combination with ionizing radiation (IR). Experimental Design: Androgen-induced DNA damage was assessed by comet assays and γH2A.X foci formation. Effects of androgen stimulation and radiation were determined in vitro and in vivo with xenograft models. Results: We document that androgen treatment of androgen-deprived prostate cancer cell lines resulted in a dose- and time-dependent induction of widespread DSBs. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell-cycle progression. In vitro models demonstrated a synergistic interaction between IR and androgen stimulation when IR is given at a time point corresponding with high levels of androgen-induced DSB formation. Furthermore, in vivo studies showed a significant improvement in tumor growth delay when radiation was given shortly after androgen repletion in castrated mice. Conclusions: These results suggest a potential cooperative effect and improved tumor growth delay with androgen-induced DSBs and radiation with implications for improving the therapeutic index of prostate cancer radiation therapy.

Original languageEnglish (US)
Pages (from-to)3310-3319
Number of pages10
JournalClinical Cancer Research
Volume22
Issue number13
DOIs
StatePublished - Jul 1 2016

Fingerprint

Ionizing Radiation
Androgens
Prostatic Neoplasms
Radiation
Radiotherapy
Growth
Neoplasms
Comet Assay
Androgen Receptors
Standard of Care
Heterografts
DNA Damage
Testosterone
Cell Cycle
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. / Hedayati, Mohammad; Haffner, Michael C.; Coulter, Jonathan B.; Raval, Raju R.; Zhang, Yonggang; Zhou, Haoming; Mian, Omar; Knight, Emma J.; Razavi, Nina; Dalrymple, Susan; Isaacs, John Tod; Santos, Aileen; Hales, Russell; Nelson, William G; Yegnasubramanian, S; DeWeese, Theodore.

In: Clinical Cancer Research, Vol. 22, No. 13, 01.07.2016, p. 3310-3319.

Research output: Contribution to journalArticle

Hedayati, Mohammad ; Haffner, Michael C. ; Coulter, Jonathan B. ; Raval, Raju R. ; Zhang, Yonggang ; Zhou, Haoming ; Mian, Omar ; Knight, Emma J. ; Razavi, Nina ; Dalrymple, Susan ; Isaacs, John Tod ; Santos, Aileen ; Hales, Russell ; Nelson, William G ; Yegnasubramanian, S ; DeWeese, Theodore. / Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 13. pp. 3310-3319.
@article{5b9772003f9a4be7b54b05d874b79780,
title = "Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation",
abstract = "Purpose: The current standard of care for patients with locally advanced prostate cancer is a combination of androgen deprivation and radiation therapy. Radiation is typically given with androgen suppression when testosterone levels are at their nadir. Recent reports have shown that androgen stimulation of androgen-deprived prostate cancer cells leads to formation of double-strand breaks (DSB). Here, we exploit this finding and investigate the extent and timing of androgen-induced DSBs and their effect on tumor growth following androgen stimulation in combination with ionizing radiation (IR). Experimental Design: Androgen-induced DNA damage was assessed by comet assays and γH2A.X foci formation. Effects of androgen stimulation and radiation were determined in vitro and in vivo with xenograft models. Results: We document that androgen treatment of androgen-deprived prostate cancer cell lines resulted in a dose- and time-dependent induction of widespread DSBs. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell-cycle progression. In vitro models demonstrated a synergistic interaction between IR and androgen stimulation when IR is given at a time point corresponding with high levels of androgen-induced DSB formation. Furthermore, in vivo studies showed a significant improvement in tumor growth delay when radiation was given shortly after androgen repletion in castrated mice. Conclusions: These results suggest a potential cooperative effect and improved tumor growth delay with androgen-induced DSBs and radiation with implications for improving the therapeutic index of prostate cancer radiation therapy.",
author = "Mohammad Hedayati and Haffner, {Michael C.} and Coulter, {Jonathan B.} and Raval, {Raju R.} and Yonggang Zhang and Haoming Zhou and Omar Mian and Knight, {Emma J.} and Nina Razavi and Susan Dalrymple and Isaacs, {John Tod} and Aileen Santos and Russell Hales and Nelson, {William G} and S Yegnasubramanian and Theodore DeWeese",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-15-1147",
language = "English (US)",
volume = "22",
pages = "3310--3319",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation

AU - Hedayati, Mohammad

AU - Haffner, Michael C.

AU - Coulter, Jonathan B.

AU - Raval, Raju R.

AU - Zhang, Yonggang

AU - Zhou, Haoming

AU - Mian, Omar

AU - Knight, Emma J.

AU - Razavi, Nina

AU - Dalrymple, Susan

AU - Isaacs, John Tod

AU - Santos, Aileen

AU - Hales, Russell

AU - Nelson, William G

AU - Yegnasubramanian, S

AU - DeWeese, Theodore

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose: The current standard of care for patients with locally advanced prostate cancer is a combination of androgen deprivation and radiation therapy. Radiation is typically given with androgen suppression when testosterone levels are at their nadir. Recent reports have shown that androgen stimulation of androgen-deprived prostate cancer cells leads to formation of double-strand breaks (DSB). Here, we exploit this finding and investigate the extent and timing of androgen-induced DSBs and their effect on tumor growth following androgen stimulation in combination with ionizing radiation (IR). Experimental Design: Androgen-induced DNA damage was assessed by comet assays and γH2A.X foci formation. Effects of androgen stimulation and radiation were determined in vitro and in vivo with xenograft models. Results: We document that androgen treatment of androgen-deprived prostate cancer cell lines resulted in a dose- and time-dependent induction of widespread DSBs. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell-cycle progression. In vitro models demonstrated a synergistic interaction between IR and androgen stimulation when IR is given at a time point corresponding with high levels of androgen-induced DSB formation. Furthermore, in vivo studies showed a significant improvement in tumor growth delay when radiation was given shortly after androgen repletion in castrated mice. Conclusions: These results suggest a potential cooperative effect and improved tumor growth delay with androgen-induced DSBs and radiation with implications for improving the therapeutic index of prostate cancer radiation therapy.

AB - Purpose: The current standard of care for patients with locally advanced prostate cancer is a combination of androgen deprivation and radiation therapy. Radiation is typically given with androgen suppression when testosterone levels are at their nadir. Recent reports have shown that androgen stimulation of androgen-deprived prostate cancer cells leads to formation of double-strand breaks (DSB). Here, we exploit this finding and investigate the extent and timing of androgen-induced DSBs and their effect on tumor growth following androgen stimulation in combination with ionizing radiation (IR). Experimental Design: Androgen-induced DNA damage was assessed by comet assays and γH2A.X foci formation. Effects of androgen stimulation and radiation were determined in vitro and in vivo with xenograft models. Results: We document that androgen treatment of androgen-deprived prostate cancer cell lines resulted in a dose- and time-dependent induction of widespread DSBs. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell-cycle progression. In vitro models demonstrated a synergistic interaction between IR and androgen stimulation when IR is given at a time point corresponding with high levels of androgen-induced DSB formation. Furthermore, in vivo studies showed a significant improvement in tumor growth delay when radiation was given shortly after androgen repletion in castrated mice. Conclusions: These results suggest a potential cooperative effect and improved tumor growth delay with androgen-induced DSBs and radiation with implications for improving the therapeutic index of prostate cancer radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=84977155290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977155290&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1147

DO - 10.1158/1078-0432.CCR-15-1147

M3 - Article

C2 - 26831716

AN - SCOPUS:84977155290

VL - 22

SP - 3310

EP - 3319

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -